Theri­va’s on­colyt­ic virus suc­ceeds in pan­cre­at­ic can­cer study, but stock falls

Theri­va Bi­o­log­ics’ ex­per­i­men­tal on­colyt­ic virus treat­ment and chemother­a­py helped pa­tients in a mid-stage study stay alive longer than chemother­a­py alone.

The com­pa­ny

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER